Life Sciences & MOB Investment Surges Amidst Record Funding

By Majid Radaei, RadCRE · · Industry Insights

Despite wider market headwinds, investment in life sciences and medical office buildings (MOBs) remains robust, driven by record R&D funding and demographic shifts. Q4 2025 saw over $8.5B in M&A activity.

Life Sciences and Medical Office: A Resilient CRE Sector in 2026

The commercial real estate landscape continues to navigate macroeconomic uncertainties, yet the life sciences and medical office building (MOB) sectors demonstrably stand out for their sustained investor demand and robust fundamentals. These specialized asset classes, buoyed by unprecedented levels of pharmaceutical R&D funding, an aging global population, and technological advancements in healthcare, have attracted significant capital inflows, proving resilient against rising interest rates and broader market revaluations.

Record Funding Fuels Life Sciences Development and Acquisitions

Investment in the life sciences sector reached new heights in late 2025 and early 2026, primarily driven by continued venture capital and institutional funding into biotech and pharma. According to projections from JLL Research, global life sciences venture capital funding is expected to exceed $60 billion in 2026, creating an insatiable demand for cutting-edge laboratory and R&D space. This funding bonanza has translated into significant transaction volume. For instance, in Q4 2025, BioMed Realty, a Blackstone portfolio company, closed on over $8.5 billion in strategic acquisitions and developments across key clusters like Cambridge, Boston, and the Bay Area, underscoring the fierce competition for prime assets. Cap rates for Class A life sciences properties in core markets like Boston and San Francisco have remained compressed, often trading in the low 5% range, reflecting their perceived stability and growth potential.

MOBs: Healthcare's Enduring Need Drives Investor Interest

Medical office buildings continue to attract institutional and private capital, characterized by durable tenant demand and long-term lease structures. The aging demographic in the U.S. and an increased focus on outpatient care delivery are fundamental drivers. Data from CoStar reveals that vacancy rates for MOBs nationally hovered around 7.5% at the close of 2025, significantly lower than the broader office sector. Major players like Healthcare Realty Trust and Ventas continue to selectively acquire, focusing on properties strategically located near major hospital systems or in rapidly growing suburban areas. In a notable transaction in late 2025, a portfolio of 12 MOBs across four states, anchored by large healthcare providers, traded for approximately $350 million, achieving an unleveraged yield mirroring the stability of the sector.

Challenges and Opportunities in a Shifting Market

While demand remains strong, the higher cost of capital has introduced new considerations for developers and investors. Construction costs for specialized lab space, featuring enhanced HVAC, structural, and electrical infrastructure, can be 2-3 times that of traditional office space, pushing up rents. Lenders, while still active in the sector, are applying more stringent underwriting criteria, with bridge loan spreads for life sciences development projects currently observed in the SOFR + 300-450 basis points range for experienced sponsors. However, the mission-critical nature of these facilities and the robust tenant financial profiles often provide a compelling risk-adjusted return.

RadCRE Perspective

"The life sciences and MOB sectors are not just resilient; they're fundamentally re-setting benchmarks for defensive CRE investment," notes Majid Radaei, Founder of RAD Commercial Realty. "We've seen aggressive bidding wars for well-located, purpose-built assets, even as traditional office struggles. For our clients, we're advising a nuanced approach: while core, fully leased assets still command premium pricing, the real opportunity, particularly for value-add and distressed plays, lies in identifying dated R&D parks or underutilized office buildings in tertiary markets adjacent to talent pools. These can be repositioned into quality lab space, leveraging strong tenant pre-leasing. On the financing side, understanding the nuances of specialized construction loans versus stabilized asset debt is critical. We're actively structuring capital stacks that blend traditional bank debt, private equity, and even some non-recourse CMBS for stabilized MOB portfolios to maximize leverage while managing risk in this rate environment. The key is to partner with sponsors who truly understand the scientific and healthcare tenant needs, as this isn't a sector for generalist investors."

As the commercial real estate market moves further into 2026, the unique demand drivers and specialized nature of life sciences and medical office assets position them as preferred vehicles for capital seeking durable income streams and long-term growth.

Tags: life sciences real estate, medical office building investment, CRE investment banking, RadCRE, healthcare real estate, commercial real estate financing, biotechnology real estate

Sources: JLL Research, CoStar, Blackstone, Commercial Observer, Real Capital Analytics